This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zaditor

Novartis AG

Drug Names(s): Ketotifen fumarate, Zaditen

Description: Zaditor is a sterile ophthalmic solution containing ketotifen for topical administration to the eyes. Zaditor is a relatively selective, noncompetitive histamine antagonist (H1-receptor) and mast cell stabilizer. It inhibits the release of mediators from cells involved in hypersensitivity reactions. Decreased chemotaxis and activation of eosinophils has also been demonstrated.

Deal Structure: Novartis and Sun Pharma and Mitsubishi Tanabe
In September 2016, Sun Pharma announced the initiation of a phased transfer of manufacturing & marketing rights in Japan for the 14 long-listed/established prescription brands acquired from Novartis. These 14 prescription brands acquired by the company earlier this year will be transferred from Novartis Pharma K.K. to Sun Pharmas subsidiary in Japan beginning October 2016.

Sun Pharma has also signed a strategic distribution alliance with Mitsubishi Tanabe Pharma Corporation for these 14 prescription brands. Under this alliance, following the transfer of manufacturing & marketing rights to Sun Pharmas subsidiary in Japan, Mitsubishi Tanabe Pharma Corporation will market and distribute all the 14 brands as well as provide information on their proper use to healthcare professionals.

Partners: Sun Pharmaceutical Industries Ltd. Mitsubishi Tanabe Pharma Corporation


Zaditor News

Pink Sheet Ciba Vision Zaditor


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug